Mycophenolate Mofetil in Membranous Nephropathy and Focal Segmental
Status:
Completed
Trial end date:
2006-12-01
Target enrollment:
Participant gender:
Summary
This is a prospective randomized open-label pilot study to investigate the effect of
mycophenolate mofetil treatment in patients with abnormal urine protein excretion due to
membranous nephropathy (MN) or focal segmental glomerulosclerosis (FSGS). The change in urine
protein excretion will be the primary outcome studied. The treatment regimen comprising
prednisolone and mycophenolate mofetil will be compared with prednisolone and chlorambucil in
MN, and compared with prednisolone in FSGS. The study duration will be 12 months for each
patient.